Fibrates: Therapeutic review

British Journal of Diabetes and Vascular Disease

Volumn 6, Issue 1, 2006, Pages 11-20

  Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cardiovascular risk; Dyslipidaemia; Fibrate; Microangiography; Type 2 diabetes

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; COUMARIN DERIVATIVE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETIC RETINOPATHY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW LEVEL LASER THERAPY; LUNG EMBOLISM; METABOLIC SYNDROME X; MICROANGIOGRAPHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PANCREATITIS; PLEIOTROPY; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYMPTOMATOLOGY; THROMBOEMBOLISM; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33644784875     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514060060010201     Document Type: Review

References (53)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis 1998;41:151-74.
3. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13.
4. Steiner G. Fibrates and coronary risk reduction. Atherosclerosis 2005. Published online April 2005. doi 10.1016/j.atherosclerosis.2005.04.002.
5. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanism of action and clinical efficacy. Curr Atherosclerosis Rep 2004;6:148-57.
6. Guerin M, Bruckert E, Dolphin PJ et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalises the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996;16:763-72.
7. Barbier O, Pineda Torra I, Dugay Y et al. Pleiotrophic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:717-26.
8. Devchand P, Keller H, Peters J, Vazquez M, Gonzalez F, Wahli W. The PPARα-leucotriene B4 pathway to inflammation control. Nature 1996;384:39-43.
9. Staels B, Koenig W, Habib A et al. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998;393:790-3.
10. Marx M, Sukhova GK, Collins T, Libby P, Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-31.
11. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994;111:161-74.
12. Turpin G, Bruckert E. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. Atherosclerosis 1996;124(suppl):S83-S87.
13. Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemostat 1989;54:442-4.
14. Chapman MJ. Pharmacology of fenofibrate. Am J Med 1987;83:21-5.
15. Committee of Principal Investigators. A cooperative trial in the prevention of ischemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
16. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984;ii:600-04.
17. Frick MH, Elo O, Haapa K et al. Helsinki Heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
18. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
19. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
20. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.
21. Rubins HB, Robins SJ, Collins D for the Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996;78:572-5.
22. The BIP Study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study. Circulation 2000;102:21-7.
23. Ericsson CG, Hamsten A, Nilsson J, Grip L, de Faire U. Angiographic assessment of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.
24. Meade T, Zuhrie R, Cook C, Cooper J, on behalf of MRC General Practice Framework. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325:1-5.
25. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97.
26. Frick MH, Syvanne M, Nieminen MS et al. Prevention of angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43.
27. Guerre-Millo M, Gervois P, Raspé E et al. Peroxisome-proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000;275:16638-42.
28. Koskinen P, Manttari M, Manninen V et al. Coronary heart disease in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.
29. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597-604.
30. Elkeles RS, Diamond JR, Poulter C et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Prevention (SENDCAP) Study. Diabetes Care 1998;21:641-8.
31. Greenland P, Abrams J, Aurigemma GP et al. AHA Scientific Statement. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention: non-invasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:e16-e22.
32. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.
33. Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-7.
34. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. The FIELD Study Investigators. Cardiovascular Diabetology 2004;3:9. doi: 10.1186/1475-2840-3-9.
35. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; November 14. doi 10.1016/S0140-6736(05)67667-2.
36. World Health Organization. Diabetes mellitus: report of a WHO study group. Geneva, WHO, 1985.
37. Robins SJ, Rubins HB, Faas HF et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-17.
38. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779-85.
39. The IDF consensus worldwide definition of the metabolic syndrome. April 14, 2005. Available from: http://www.idf.org compared with fenofibrate monotherapy in severe primary hypercholesterolemia.
40. Athyros VG, Papageorgiou A, Athyrou VV et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202.
41. Derosa G, Cicero AE, Bertone G et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004;26:1599-607.
42. Vega GL, Ma PT, Cater NB et al. Effects of adding fenofibrate (200 mg/ day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956-60.
43. Grundy SM, Vega GL, Yuan Z et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95:462-8.
44. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B-65B.
45. Farnier M, Dejager S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am J Cardiol 2000;85:53-7.
46. Durrington PN, Tuomilehto J, Hamann A et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Clin Pract 2004;64:137-51.
47. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000;247:563-9.
48. Spieker LE, Noll G, Hannak M, Luscher TF. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. J Cardiovasc Pharmacol 2000;35:361-5.
49. Pauciullo P, Borgnino C, Paoletti R et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidemia (FACT study). Atherosclerosis 2000;150:429-36.
50. Wierzbicki AS, Mikhailidis DP, Wray R et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155-68.
51. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Available from www.accordtrial.org, accessed 25 September 2005.
52. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and CAD. Am J Cardiol 1998;81: 912-17.
53. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet 2005; November 14. doi 10.16/ So140-6736(05)67668-4.